Effect of aging on the sensitivity of growth hormone secretion to insulin-like growth factor-I negative feedback

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 9, 1997, Pages 2996-3004

  Chapman, Ian M ^a,e   Hartman, Mark L ^a   Pezzoli, Suzan S ^a   Harrell Jr , Frank E ^b   Hintz, Raymond L ^c   Alberti, K G M M ^d   Thorner, Michael O ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN C;

ADULT; AGED; AGING; ARTICLE; BODY COMPOSITION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HUMAN; MALE; NEGATIVE FEEDBACK; PRIORITY JOURNAL;

3-HYDROXYBUTYRIC ACID; ADULT; AGING; BLOOD GLUCOSE; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS, NONESTERIFIED; FEEDBACK; FEMALE; GLUCOSE; HUMAN GROWTH HORMONE; HUMANS; HYDROXYBUTYRATES; INFUSIONS, INTRAVENOUS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; MALE; OSMOLAR CONCENTRATION; RECOMBINANT PROTEINS;

EID: 0030953395     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.82.9.2996     Document Type: Article

References (53)

1. Ho KY, Evans WS, Blizzard RM, et al. 1987 Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab. 64:51-58.
2. Iranmanesh A, Lizarralde G, Veldhuis JD. 1991 Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the halt-life of endogenous GH in healthy men. J Clin Endocrinol Metab. 73:1081-1088.
3. Zadik Z, Chalew SA, McCarter Jr RJ, Meistas M, Kowarski AA. 1985 The influence of age on the 24-hour integrated concentration of growth hormone in normal individuals. J Clin Endocrinol Metab. 60:513-516.
4. Corpas E, Harman SM, Blackman MR. 1993 Human growth hormone and human aging. [Review]. Endocr Rev. 14:20-39.
5. Hoffman DM, O'Sullivan AJ, Baxter RC, Ho KK. 1994 Diagnosis of growth-hormone deficiency in adults. Lancet. 343:1064-1068.
6. Thorner MO, Bengtsson BA, Ho KY, et al. 1995 The diagnosis of growth hormone deficiency (GHD) in adults. J Clin Endocrinol Metab. 80:3097-3098.
7. Rudman D, Feller AG, Nagraj HS, et al. 1990 Effects of human growth hormone in men over 60 years old. N Engl J Med. 323:1-6.
8. Jorgensen JOL, Pedersen SA, Thuesen L, et al. 1989 Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet. 1:1221-1225.
9. Salomon F, Cuneo RC, Hesp R, Sonksen PH. 1989 The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med. 321:1797-1803.
10. Bengtsson BA, Eden S, Lonn L, et al. 1993 Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab. 76:309-317.
11. Johannsson G, Rosen T, Bosaeus I, Sjostrom L, Bengtsson BA. 1996 Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. J Clin Endocrinol Metab. 81:2865-2873.
12. Baum HBA, Biller BMK, Finkelstein JS, et al. 1996 Effects of physiologic growth hormone replacement therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. Ann Intern Med. 125:883-890.
13. Rosen T, Bengtsson BA. 1990 Premature mortality due to cardiovascular disease in hypopituitarism. Lancet. 336:285-288.
14. Holloway L, Butterfield G, Hintz RL, Gesundheit N, Marcus R. 1994 Effects of recombinant human growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women. J Clin Endocrinol Metab. 79:470-479.
15. Papadakis MA, Grady D, Black D, et al. 1996 Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med. 124:708-716.
16. Welle S, Thornton C, Statt M, McHenry B. 1996 Growth hormone increases muscle mass and strength but does not rejuvenate myofibrillar protein synthesis in healthy subjects over 60 years old. J Clin Endocrinol Metab. 81:3239-3243.
17. Guler HP, Zapf J, Froesch ER. 1987 Short-term metabolic effects of recombinant human insulin-like growth factor in healthy adults. N Engl J Med. 317:137-140.
18. Zenobi PD, Graf S, Ursprung H, Froesch ER. 1992 Effects of insulin-like growth factor I on insulin secretion and renal function in normal human subjects. Proc Natl Acad Sci USA. 86:2868-2872.
19. Hartman ML, Clayton PE, Johnson ML, et al. 1993 A low dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans. J Clin Invest. 91:2453-2462.
20. Bermann M, Jaffe CA, Tsai W, DeMott-Friberg R, Barkan AL. 1994 Negative feedback regulation of pulsatile growth hormone secretion by insulin-like growth factor I. Involvement of hypothalamic somatostatin. J Clin Invest. 94:138-145.
21. Clemmons DR, Klibanski A, Underwood LE, et al. 1981 Reduction of plasma immunoreactive somatomedin-C during fasting in humans. J Clin Endocrinol Metab. 53:1247-1250.
22. Ho KY, Veldhuis JD, Johnson ML, et al. 1988 Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man. J Clin Invest. 81:968-975.
23. Straus DS, Takemoto CD. 1990 Effect of fasting on insulin-like growth factor-I (IGF-I) and growth hormone receptor mRNA levels and IGF-I gene transcription in rat liver. Mol Endocrinol. 4:91-100.
24. Guevara-Aguirre J, Rosenbloom AL, Vaccarello MA, et al. 1991 Growth hormone receptor deficiency (Laron syndrome): clinical and genetic characteristics. Acta Paediatr Scand. Suppl. 377:96-103.
25. Dunger DB, Edge JA, Pal R, Taylor AM, Holly JM, Matthews DR. 1991 Impact of increased growth hormone secretion on carbohydrate metabolism in adolescents with diabetes. Acta Paediatr Scand. Suppl. 377:69-77.
26. Lanes R, Recker B, Fort P, Lifshitz F. 1985 Impaired somatomedin generation test in children with insulin-dependent diabetes mellitus. Diabetes. 34:156-160.
27. Vaccarello MA, Diamond Jr FB, Guevara-Aguirre J, et al. 1993 Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-1 in growth hormone receptor deficiency/Laron syndrome. J Clin Endocrinol Metab. 77:273-280.
28. Cheetham TD, Jones J, Taylor AM, Holly J, Matthews DR, Dunger DB. 1993 The effects of recombinant insulin-like growth factor I administration on growth hormone levels and insulin requirements in adolescents with type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 36:678-681.
29. Hartman ML, Veldhuis JD, Johnson ML, et al. 1992 Augmented growth hormone (GH) secretory burst frequency and amplitude mediate enhanced GH secretion during a two-day fast in normal men. J Clin Endocrinol Metab. 74:757-765.
30. Hartman ML, Pezzoli SS, Hellmann PJ, Suratt PM, Thorner MO. 1996 Pulsatile growth hormone secretion in older persons is enhanced by fasting without relationship to sleep stages. J Clin Endocrinol Metab. 81:2694-2701.
31. Faria ACS, Bekenstein LW, Booth Jr RA, et al. 1992 Pulsatile growth hormone release in normal women. Clin Endocrinol (Oxf). 36:591-596.
32. DeFronzo RA, Tobin JD, Andres R. 1979 Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 237:E214-223.
33. Chapman IM, Hartman ML, Straume M, Johnson ML, Veldhuis JD, Thorner MO. 1994 Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than women. J Clin Endocrinol Metab. 78:1312-1319.
34. Kaiser L. 1989 Adjusting for baseline: change or percentage change? Stat Med. 8:1183-1190.
35. Michels KM, Lee WH, Seltzer A, Saavedra JM, Bondy CA. 1993 Up-regulation of pituitary [125I]insulin-like growth factor-I (IGF-I) binding and IGF binding protein-2 and IGF-I gene expression by estrogen. Endocrinology. 132:23-29.
36. Olchovsky D, Song J, Gelato MC, et al. 1993 Pituitary and hypothalamic insulin-like growth factor-I (IGF-I) and IGF-I receptor expression in food-deprived rats. Mol Cell Endocrinol. 93:193-198.
37. Morgan DJ, Bray KM. 1994 Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin Pharmacokinet. 26:292-307.
38. Cohick WS, Clemmons DR. 1993 The insulin-like growth factors. Annu Rev Physiol. 55:131-153.
39. Baxter RC, Martin JL. 1986 Radioimmunoassay of growth hormone-dependent insulin-like growth factor binding protein in human plasma. J Clin Invest. 78:1504-1512.
40. Rutanen EM, Karkkainen T, Stenman UH, Yki-Jarvinen H. 1993 Aging is associated with decreased suppression of insulin-like growth factor binding protein-1 by insulin. J Clin Endocrinol Metab. 77:1152-1155.
41. Hall K, Lundin G, Povoa G. 1988 Serum levels of the low molecular weight form of insulin-like growth factor binding protein in healthy subjects and patients with growth hormone deficiency, acromegaly and anorexia nervosa. Acta Endocrinol (Copenh). 118:321-326.
42. Juul A, Main K, Blum WF, Lindholm J, Ranke MB, Skakkebaek NE. 1994 The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clin Endocrinol (Oxf). 41:85-93.
43. Juul A, Flyvberg A, Frystyk J, Muller J, Skakkebaek NE. 1996 Serum concentrations of free and total insulin-like growth factor-I, IGF binding proteins -1 and -3 and IGFBP protease activity in boys with normal or precocious puberty. Clin Endocrinol (Oxf). 44:515-523.
44. Boulware SD, Tamborlane WV, Rennert NJ, Gesundheit N, Sherwin RS. 1994 Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose-response relationships in healthy young and middle-aged adults. J Clin Invest. 93:1131-1139.
45. Pontiroli AE, Lanzi R, Monti LD, Sandoli E, Pozza G. 1991 Growth hormone (GH) autofeedback on GH response to GH-releasing hormone. Role of free fatty acids and somatostatin. J Clin Endocrinol Metab. 72:492-495.
46. Lee EJ, Nam SY, Kim KR, et al. 1995 Acipimox potentiates growth hormone (GH) response to GH-releasing hormone with or without pyridostigmine by lowering serum free fatty acid in normal and obese subjects, J Clin Endocrinol Metab. 80:2495-2498.
47. Pontiroli AE, Manzoni MF, Malighetti ME, Lanzi R. 1996 Restoration of growth hormone (GH) response to GH-releasing hormone in elderly and obese subjects by acute pharmacological reduction of plasma free fatty acids. J Clin Endocrinol Metab. 81:3998-4001.
48. Reichlin S. 1974 Regulation of somatotrophic hormone secretion. In: Knobil E, Wawyer WH, eds. Handbook of physiology, Section 7, Vol. IV. Washington, DC: American Physiological Society; 405-447.
49. Imaki T, Shibasaki T, Shizume K, et al. 1985 The effect of free fatty acids on growth hormone (CH)-releasing hormone-mediated GH secretion in man. J Clin Endocrinol Metab. 60:290-293.
50. Hartman ML, Thorner MO. Fasting-induced enhancement of pulsatile growth hormone (GH) secretion is rapidly abolished by refeeding. Proc 72nd Meeting of The Endocrine Society, Atlanta, GA, 1990, p 55.
51. Guler HP, Zapf J, Schmid C, Froesch ER. 1989 Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. Acta Endocrinol (Copenh). 121:753-758.
52. Baxter RC, Hizuka N, Takano K, Holman SR, Asakawa K. 1993 Responses of insulin-like growth factor binding proton-1 (IGFBP-1) and the IGFBP-3 complex to administration of insulin-like growth factor-I. Acta Endocrinol (Copenh). 128:101-108.
53. Young SC, Underwood LE, Celniker A, Clemmons DR. 1992 Effects of recombinant insulin-like growth factor-I (IGF-I) and growth hormone on serum IGF-binding proteins in calorically restricted adults. J Clin Endocrinol Metab. 75:603-608.